Form 4: Scholar Rock CSO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Scholar Rock Holding Corp's Chief Scientific Officer, Mo Qatanani, executed a pre-planned sale of 136,462 common shares following option exercises.
Summary
- Mo Qatanani, Chief Scientific Officer of Scholar Rock Holding Corp (SRRK), reported transactions on December 4, 2025.
- The transactions were executed under a Rule 10b5-1 trading plan adopted on March 31, 2025.
- Qatanani exercised multiple stock options to acquire a total of 136,462 shares of common stock at exercise prices ranging from $4.86 to $35.15.
- Immediately following the option exercises, Qatanani sold all 136,462 acquired common shares at a weighted average price of $45.2125 per share.
- The sale price ranged from $45.00 to $45.46 per share.
- Following these transactions, Qatanani's direct beneficial ownership of common stock is zero, with 108,964 Restricted Stock Units (RSUs) remaining.
- Qatanani also holds various unvested stock options, including 1,282 shares at a $26.05 exercise price, 1,407 shares at $18.08, 14,063 shares at $10.00, 53,036 shares at $15.75, and 34,820 shares at $35.15.
Sentiment
Score: 5
Explanation: Neutral. The transaction is a pre-planned insider sale, which is a routine event for executives managing their personal finances. While a sale reduces insider ownership, the 10b5-1 plan mitigates any immediate negative signal. The executive is monetizing vested equity, which is a positive for the individual, but not necessarily for the stock's immediate outlook.
Positives
- The executive monetized a significant portion of their equity compensation, indicating personal financial gain.
- The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which demonstrates adherence to insider trading regulations and reduces the perception of opportunistic selling.
Negatives
- A significant insider sale of common stock by a Chief Scientific Officer could be perceived negatively by some investors, even if pre-planned.
- The executive's direct beneficial ownership of common stock is now zero, holding only RSUs and unvested options.
Future Outlook
This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports insider trading activity.
Management Comments
- The transaction was effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2025.
Industry Context
Insider transactions, particularly pre-planned sales under Rule 10b5-1, are common in the biotechnology and pharmaceutical sectors, where executive compensation often includes significant equity components. These sales allow executives to diversify their personal holdings and manage liquidity without necessarily implying a negative outlook on the company's prospects, especially when executed under a pre-arranged plan.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Adoption | The Chief Scientific Officer adopted a Rule 10b5-1 trading plan on March 31, 2025, to pre-arrange the sale of equity securities. | 03/31/2025 | Enhances compliance with insider trading laws by providing an affirmative defense against claims of trading on material non-public information. |
Stakeholder Impact
- Shareholders: May observe a reduction in direct common stock ownership by a key executive, though mitigated by the pre-planned nature of the sale.
- Employees: No direct impact on employees, but may note executive's equity management.
- Management: The Chief Scientific Officer has diversified personal holdings while retaining significant unvested equity.
Next Steps
- Continued vesting of remaining stock options and RSUs as per their respective schedules.
- Potential future transactions by the reporting person under the existing or new 10b5-1 plans.
Key Dates
| Date | Description |
|---|---|
| 04/01/2022 | First vesting event for stock option with $18.08 exercise price. |
| 01/05/2023 | First vesting event for stock option with $26.05 exercise price. |
| 04/01/2023 | First vesting event for stock option with $10.00 exercise price. |
| 04/01/2024 | First vesting event for stock option with $15.75 exercise price. |
| 03/31/2025 | Rule 10b5-1 trading plan adopted by the Reporting Person. |
| 04/01/2025 | First vesting event for stock option with $35.15 exercise price. |
| 12/04/2025 | Date of reported transactions (option exercises and common stock sale). |
| 12/05/2025 | Signature date of the filing. |
| 10/26/2031 | Expiration date for stock option with $26.05 exercise price. |
| 02/14/2032 | Expiration date for stock option with $18.08 exercise price. |
| 06/16/2032 | Expiration date for stock option with $4.86 exercise price. |
| 10/10/2032 | Expiration date for stock option with $7.62 exercise price. |
| 02/13/2033 | Expiration date for stock option with $10.00 exercise price. |
| 12/12/2034 | Expiration date for stock option with $15.75 exercise price. |
| 03/10/2035 | Expiration date for stock option with $35.15 exercise price. |
Keywords
Scholar Rock Holding Corp, SRRK, Form 4, Insider Trading, Stock Options, Equity Compensation, Rule 10b5-1, Chief Scientific Officer, Mo Qatanani, Share Sale, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.